新的研究表明,在用新型CAR-T疗法治疗淋巴瘤方面有可能取得突破。 New studies show potential breakthroughs in treating lymphoma with novel CAR-T therapies.

最近的两项研究显示,针对淋巴瘤的治疗结果很有希望。 Two recent studies show promising results for treatments targeting lymphoma. NKtar治疗公司报告说,NKTR-255在CD19指导的CAR-T治疗后使用后,复发性或易腐性大型B细胞淋巴瘤患者的完全反应率提高了。 Nektar Therapeutics reported that NKTR-255, when used after CD19-directed CAR-T therapy, increased complete response rates in patients with relapsed or refractory large B-cell lymphoma. 同时,加拉帕戈斯宣布了对GLPG5101(CD19 CAR T细胞疗法)进行第一阶段半研究的积极成果,该研究针对的是复发或患非霍格金淋巴瘤的病人。 Meanwhile, Galapagos announced positive outcomes from their Phase 1/2 study of GLPG5101, a CD19 CAR T-cell therapy, for patients with relapsed or refractory non-Hodgkin lymphoma.